S100A7 can either promote or suppress breast cancer cell proliferation through distinct modulation of the NF-κB – miR-29b – p53 pathway in ER− MDA-MB-231 and ER+ MCF7 cells, respectively (summarized in Figure 7). Here, TP53 is linked to breast carcinoma.